Dr. Claudia Haydée Arce Salinas, medical oncologist at the National Institute of Cancerology (INCan), participated in the High-Level Forum on Public Policies for Triple Negative Breast Cancer (TNBC) in Mexico. In this event, Dr. Arce Salinas highlighted the importance of timely diagnosis and personalized strategies for the treatment of this disease.
According to Dr. Arce Salinas, not all patients with triple-negative tumors need immediate surgery, as they may benefit from initial chemotherapy. During an exclusive interview, the oncologist mentioned the challenges that Mexico faces regarding the diagnosis and treatment of triple-negative breast cancer.
Dr. Arce Salinas emphasized the implementation of strategies to achieve early diagnosis and multidisciplinary management, including necessary genomic diagnostics for the treatment of these patients. She highlighted the importance of pathologists providing detailed information about the histological type and the status of estrogen, progesterone, HER2, and Ki-67 receptors to establish the best therapeutic strategy for each patient.
One of the main challenges identified by Dr. Arce Salinas is the need for timely diagnosis. This means that patients with suspected cancer should receive prompt attention to obtain a biopsy with complete information in less than 30 days. With treatment starting in less than 90 days, it has been shown that the chances of mortality are reduced by 4%.
In summary, Dr. Arce Salinas stressed the importance of personalized strategies and appropriate treatment for patients with triple-negative breast cancer, as well as the need for timely diagnosis to improve outcomes and reduce mortality associated with this disease.
